- Call: (970) 716-1173
- 6500 W 29th St Suite 280, Greeley, CO 80634
- Monday - Friday (Morning/Evening Availability)
The leading provider of Tirzepatide Medical Weight Loss in Greeley Co. Helping patients lose weight and keep it off.
“A phase 3 clinical trial found a high dose of tirzepatide helped patients lose 22.5% of their body weight on average, or about 52 pounds, better than any medication currently on the market.“
Tirzepatide, also sold under other various trade marks like Mounjaro, is an FDA aprroved diabetic medication that was also discovered to provide exceptional weight loss. Benefits of Tirzepatide include:
Decreased appetite and cravings, Weight loss, A1C reduction, Improved cardiometabolic measures
What is included?
Tirzepatide is a new medication that was FDA approved in May 2022 to treat Type 2 diabetes and is set to be FDA approved for weight loss in 2023. Likely to become the best selling medication of all time and a “game-changer” in weight loss.
Tirzepatide is an injectable medication which, when used in combination with diet and exercise is an extremely effective medical weightloss medication. Tirzepatide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, which mimic the hormone GLP-1 in your body to lower blood sugar levels after eating. Even if you are not diabetic or have insulin resistance Tirzepatide has been shown to melt fat and contributes to incredible weight loss! This mechanism also targets areas in the brain that regulate appetite and food intake. Because of the combination of two peptides over other GLP-1 aganoist peptides it has had the most effective and profound weight loss results, considerably higher than even Semaglutide.
Glucagon-like peptide 1 (GLP-1) is a hormone that causes dramatic effects on the regulation of blood sugar by stimulating glucose-dependent insulin secretion. Insulin is a hormone that promotes sugar uptake by the cells, stores sugar as glycogen, promotes the building of fat, and signals the body to build skeletal muscle. In addition, GLP-1 inhibits glucagon release (which slows down the release of sugar into the blood so that you burn more fat), slow down gastric emptying (makes you feel fuller longer), and suppresses appetite.
Tirzepatide acts in the following ways:
● Delays how quickly our stomachs digest food. Leading to a feeling of fullness and satisfaction with smaller meal sizes.
● Slows intestinal motility so you will feel fuller longer after meals.
● Dual action receptor allows for lower blood sugars, in part by reducing the production of sugar in the liver.
● Stimulates insulin secretion by the pancreas.
● GIP increases energy expenditure, resulting in weight loss reductions
GLP-1 agonists like Tirzepatide help to control blood sugar, but those taking them also tend to lose weight. GLP-1, the key hormone involved, slows down how fast your stomach empties food. In addition to causing the pancreas to release insulin, Semaglutide blocks the hormone that signals the liver to release sugar. Together, these functions help you feel less hungry, eat less, and lose weight.
All patients start on the lowest dose of Tirzepatide at 2.5mg (25U) injected subcutaneously into belly fat once weekly. Patients increase 2.5mg (25U) monthly if well tolerated (slower if nauseous or gi upset), up to a total of 15mgs (150U). The longterm weightloss in the clinical trials without diet and exercise modification was phenomenal.
Set up an initial consultation where questions are answered and lab work is ordered.
Follow-up appointment to discuss in-depth lab results and YOUR personalized plan.
Depending on the therapy chosen, follow-up is initially in eight weeks then every six months. Some patients only require labs and follow-up yearly depending on how YOU feel!
Spark Hormone Therapy uses only bioidentical hormones to restore hormones in both men and women. Optimization of hormones to optimal levels is essential to alleviate common symptoms of aging and to attain health and longevity.